Skip to main content

Prinicipal Investigator, Michael House, MD, Receives an SMFM/ABOG Bridge Grant

November 24, 2022

Michael House, MD, has been recognized as an expert in the uterine cervix, has received an SMFM/ABOG Bridge Grant entitled “Novel tools for studying cervical function and dysfunction during pregnancy.”

A headshot of Dr. Michael House
Michael House, MD

The goal of the project is to gain critical insights into mechanisms of preterm birth where cervical dysfunction is the cause. Dr. House, a principal investigator at Tufts Medical Center, has been recognized as an expert in the uterine cervix.

Dr. House is a specialist in high-risk pregnancy in Maternal Fetal Medicine and received recognition as a "Top Doctor" in 2022 from from Boston Magazine in Maternal Fetal Medicine. His research interests include:

  • design and evaluation of three-dimensional models of cervical tissue to study remodeling of the cervical extracellular matrix
  • investigation of the cervical biomechanical function using mechanical modeling techniques
  • study of the barrier properties of cervical mucus as it relates to protection against intrauterine infection
  • development of novel therapies such as injectable biomaterials to augment cervical function during pregnancy

“Normal cervical function is critical for a healthy pregnancy but premature cervical shortening and dilation is associated with preterm birth, which affects 10% of pregnancies in the United States. As a clinician and a researcher, I am so grateful for grants like this to study this problem, Dr. House said.

Sabrina Craigo and Saisha Cardoza
Patient Stories
Saisha’s Story: Two Generations of Care and Trust
October 24, 2025
From a 1 lb preemie to a proud mom of twins, Saisha’s story comes full circle with the same doctor who delivered her.
Two people standing with a bookshelf behind them.
Articles
Tufts Medical Center-Led Study Identifies Safer Path Forward for Cancer Patients at Risk of Heart Disease
August 6, 2025
Tufts Medical Center researchers find safer cancer drug option for patients at risk of heart disease, identifying a key mechanism behind treatment-related cardiac events.
Doctor in front of color background with Tufts Medicine brand.
Articles
Tufts Medical Center Research Uncovers Breakthrough Strategy to Reprogram Prostate Cancer
July 23, 2025
New bispecific antibody therapy developed by Dr. Paul Mathew and team prompts immune system to attack aggressive tumors—and may pave the way for treating other cancers

Be among the first to know

Enjoy the latest health updates from Tufts Medicine by signing up for our e-newsletter today.

Jump back to top